Trial Profile
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2024
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary) ; Donepezil
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
- Acronyms LUCINDA
- 22 Apr 2024 Planned primary completion date changed from 1 Feb 2025 to 1 Dec 2025.
- 01 Aug 2021 Trial design published in the Contemporary Clinical Trials
- 31 Jul 2020 Planned number of patients changed from 180 to 150.